Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer
Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that it has appointed Daniel Hood as Chief Legal Officer. Dan is a highly experienced lawyer with more than 13 years’ experience working in-house within the pharmaceutical and life sciences sector which follows 10 years in private practice.
“It has been a transformational time for Achilles as we progress both our THETIS study in melanoma and our CHIRON study in non-small cell lung cancer through clinical development,” said Dr Iraj Ali, CEO of Achilles. “Dan will be a great asset to the team as we grow the Company, broaden our pipeline into new indications and explore future strategic relationships.”
Dan Hood, Chief Legal Officer of Achilles, added: “Achilles Therapeutics is at the forefront of transforming cancer treatment by targeting clonal neoantigens to develop personalised T cell therapies. I am delighted to join such an experienced and motivated team on their journey to revolutionising cancer care.”
Dan joins Achilles from Intercept Pharmaceuticals where he was Vice President, Legal with responsibility for all legal matters outside the United States. He has extensive experience as an in-house lawyer, including leadership and business partnering roles within GE Healthcare and Gilead Sciences. Dan has an MA in Law from Cambridge University and is enrolled as a solicitor in England & Wales and Ireland.